TrippBio, a biotechnology company, is launching a crowdfunding investment opportunity to develop a treatment for COVID-19, it was reported on Wednesday.
The company has a repurposed Food and Drug Administration drug (TD213) that has indicated high efficiency in eliminating COVID-19 in preliminary testing. The firm requires public support to start clinical trials and prepare the drug for commercialisation.
According to the company, research results have revealed that the product is able to prevent and decrease COVID-19 disease severity by reducing virus replication. Laboratory studies have indicated that TD213 can reduce the viral load by 90%.
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study